Association of interleukin-6 and interleukin-10 genotypes with radiographic damage in rheumatoid arthritis is dependent on autoantibody status

Arthritis and Rheumatism

Volumn 56, Issue 8, 2007, Pages 2549-2556

  Marinou, I ^a   Healy, J ^a   Mewar, D ^a   Moore, D J ^a   Dickson, M C ^b   Binks, M H ^b   Montgomery, D S ^b   Walters, K ^a   Wilson, A G ^a,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 6; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE N22; RHEUMATOID FACTOR; SELENOPROTEIN; SELENOPROTEIN S; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ANTIBODY PRODUCTION; ARTICLE; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOREGULATION; JOINT DESTRUCTION; JOINT RADIOGRAPHY; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; MODIFIED LARSEN SCORE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RHEUMATOID FACTOR;

EID: 34547749806     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22814     Document Type: Article

References (37)

1. Vyse TJ, Todd JA. Genetic analysis of autoimmune disease [review]. Cell 1996;85:311-8.
2. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30: 1205-13.
3. Weyand CM, McCarthy TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995;95:2120-6.
4. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004;75:330-7.
5. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-20.
6. Larsen A. Radiological grading of rheumatoid arthritis: an interobserver study. Scand J Rheumatol 1973;2:136-8.
7. Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, et al. Independent associations of anti-cyclical citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 2006;8:R128.
8. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1473-7.
9. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
10. Van der Helm-van Mil AH, Kern M, Gregersen PK, Huizinga TW. Variation in radiologic joint destruction in rheumatoid arthritis differs between monozygotic and dizygotic twins and pairs of unrelated patients. Arthritis Rheum 2006;54:2028-30.
11. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-8.
12. Barton A, John S. Approaches to identifying genetic predictors of clinical outcome in rheumatoid arthritis. Am J Pharmacogenomics 2003;3:181-91.
13. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
14. Curran JE, Jowett JB, Elliott KS, Gao Y, Gluschenko K, Wang J, et al. Genetic variation in selenoprotein S influences inflammatory response. Nat Genet 2005;37:1234-41.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
16. Kishimoto T. Interleukin-6: from basic science to medicine - 40 years in immunology [review]. Annu Rev Immunol 2005;23:1-21.
17. Wood NC, Symons JA, Dickens E, Duff GW. In situ hybridization of IL-6 in rheumatoid arthritis. Clin Exp Immunol 1992;87:183-9.
18. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992;19:22-5.
19. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
20. Ogilvie EM, Fife MS, Thompson SD, Twine N, Tsoras M, Moroldo M, et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multi-center study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 2003;48:3202-6.
21. Pascual M, Nieto A, Mataran L, Balsa A, Pascual-Salcedo D, Martin J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 2000;1:338-40.
22. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
23. Pawlik A, Wrzesniewska J, Florczak M, Gawronska-Szklarz B, Herczynska M. IL-6 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol 2005;34:109-13.
24. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor [review]. Annu Rev Immunol 2001;19:683-765.
25. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994;179:1517-27.
26. Huizinga TW, Keijsers V, Yanni G, Hall M, Ramage W, Lanchbury J, et al. Are differences in interleukin 10 production associated with joint damage? Rheumatology (Oxford) 2000;39:1180-8.
27. Keravala A, Lechman ER, Nash J, Mi Z, Robbins PD. Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis. Arthritis Res Ther 2006;8:R91.
28. Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996;39: 495-503.
29. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349: 170-3.
30. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Nat Acad Sci U S A 1998;95:9465-70.
31. Kurreeman FA, Schonkeren JJ, Heijmans BT, Toes RE, Huizinga TW. Transcription of the IL10 gene reveals allele-specific regulation at the mRNA level. Hum Mol Genet 2004;13:1755-62.
32. Eskdale J, McNicholl J, Wordsworth P, Jonas B, Huizinga T, Field M, et al. Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility [letter]. Lancet 1998;352:1282-3.
33. Cantagrel A, Navaux F, Loubet-Lescoulie P, Nourhashemi F, Enault G, Abbal M, et al. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999;42:1093-100.
34. Majka DS, Holers VM. Can we accurately predict the development of rheumatoid arthritis in the preclinical phase? Arthritis Rheum 2003;48:2701-5.
35. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005;77:1044-60.
36. Orozco G, Sanchez E, Gonzalez-Gay MA, Lopez-Nevot MA, Torres B, Caliz R, et al. Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 2005;52:219-24.
37. Hinks A, Worthington J, Thomson W. The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis. Rheumatology (Oxford) 2006;45:365-8.